Experiments performed on a mouse model of pancreatic cancer and cell lines proved both molecules to enhance low-dose paclitaxel effects by increasing apoptosis in tumor cells or reducing interleukin-6 levels, respectively. Here, IL6 is linked to pancreatic neoplasm.